Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility

Cancer Research

Volumn 58, Issue 20, 1998, Pages 4497-4504

  Ross, Ronald K ^a,c   Pike, Malcolm C ^a   Coetzee, Gerhard A ^a   Reichardt, Juergen K V ^a   Yu, Mimi C ^a   Feigelson, Heather ^a   Stanczyk, Frank Z ^a   Kolonel, Laurence N ^b   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; STEROID 5BETA REDUCTASE;

ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; BIOLOGICAL MODEL; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HORMONE TRANSPORT; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; REVIEW;

3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; CHOLESTENONE 5 ALPHA-REDUCTASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MODELS, GENETIC; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 0032532090     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Bittner, J. J. The causes and control of mammary cancer in mice. Harvey Lect., 42: 221-246, 1947.
2. Huggins, C., and Hodges, C. V. Studies on prostatic cancer: effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
3. Henderson, B. E., Ross, R. K., Pike, M. C., and Casagrande, J. T. Endogenous hormones as a major factor in human cancer. Cancer Res., 42: 3232-3239, 1982.
4. Kelsey, J., and Bernstein, L. Epidemiology and prevention of breast cancer. Annu. Rev. Public Health, 17: 47-67, 1996.
5. Grady, D., and Ernster, V. L. Endometrial cancer. In: D. Schottenfeld and J. F. Fraumeni (eds.), Cancer Epidemiology and Prevention, pp. 1058-1089. New York: Oxford University Press, 1996.
6. Bernstein, L., and Ross, R. K. Endogenous hormones and breast cancer risk. Epidemiol. Rev., 15: 48-65, 1993.
7. Cook, P. J., Doll, R., and Fellingham, S. A. A mathematical model for the age distribution of cancer in man. Int. J. Cancer, 4: 93-112, 1969.
8. Ross, R. K., and Schottenfeld, D. Prostate cancer. In: D. Schottenfeld and J. F. Fraumeni (eds.), Cancer Epidemiology and Prevention, pp. 1180-1206. New York: Oxford University Press, 1996.
9. Shimizu, H., Ross, R. K., and Bernstein, L. Underestimation of the incidence rate of prostate cancer in Japan. Jpn. J. Cancer Res., 82: 483-485, 1991.
10. Bernstein, L., and Ross, R. K. Cancer in Los Angeles County: A Portrait of Incidence and Mortality, 1972-1987. Los Angeles, CA: Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, 1991.
11. Henderson, B. E., Ross, R. K., and Bernstein, L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res., 48: 246-253, 1988.
12. Preston-Martin, S., Pike, M. C., Ross, R. K., and Henderson, B. E. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ. Health Perspect., 101 (Suppl. 5): 137-138, 1993.
13. Coffey, D. S. Physiological control of prostatic growth: an overview, In: Prostate Cancer, Vol. 48. UICC Technical Report Series. Geneva: International Union Against Cancer, 1979.
14. Coffey, D. S. The molecular biology of the prostate. In: H. Lepor and R. K. Lawson (eds.), Prostate Disease, pp. 28-56. Philadelphia: Saunders, 1993.
15. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37: 1929-1933, 1977.
16. Gingrich, J. R., Barrios, R. J., Morton, R. A., Bryce, B. F., De Mayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., and Greenberg, N. M. Metastatic prostate cancer in a transgenic model. Cancer Res., 56: 4096-4102, 1996.
17. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst., 88: 1118-1126, 1996.
18. Henderson, B. E., Bernstein, L., Ross, R. K., DePue, R. H., and Judd, H. L. The early in-utero estrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br. J. Cancer, 57: 216-218, 1988.
19. Ross, R. K., Bernstein, L., Judd, H., Hanisch, R., Pike, M. C., and Henderson, B. E. Serum testosterone levels in healthy young black and white men. J. Natl. Cancer Inst., 70: 45-48, 1986.
20. Pike, M. C., Krailo, M. D., Henderson, B. E., Casagrande, J. T., and Hoel, D. G. 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature (Lond.), 303: 767-770, 1983.
21. Ross, R. K., Bernstein, L., Lobo, R. A., Shimizu, H., Stanczyk, F. Z., Pike, M. C., and Henderson, B. E. 5-α Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet, 339: 887-889, 1992.
22. Lookingbill, D. P., Deniers, L. M., Wang, C., Leung, A., Rittmaster, R. S., and Santen, R. J. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J. Clin. Endocrinol. Metab., 72: 1242-1248, 1991.
23. Ross, R. K., and Coetzee, G. A. The epidemiology and etiology of prostate cancer. In: Z. Petrovich, L. Baert, and L. W. Brady (eds.), Diagnostic Imaging and Radiation Oncology, pp. 1-11. Berlin: Springer-Verlag, 1996.
24. Wilson, J. D., Griffin, J. E., and Russell, D. W. Steroid 5α-reductase 2 deficiency. Br. J. Cancer, 14: 577-593, 1993.
25. Thigpen, A. E., Davis, D. L., Gautier, T., Imperato-McGinley, J., and Russell, D. W. The molecular basis of steroid 5-α reductase deficiency in a large Dominican kindred. N. Engl. J. Med., 327: 1216-1219, 1992.
26. Davis, D. L., and Russell, D. W. Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2). Hum. Mol. Genet., 2: 820, 1993.
27. Reichardt, J. K. V., Makridakis, N., Henderson, B. E., Yu, M. C., Pike, M. C., and Ross, R. K. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res., 55: 3973-3975, 1995.
28. Ross, R. K., Coetzee, G. A., Reichardt, J., Skinner, E., and Henderson, B. E. Does the racial-ethnic variation in prostate cancer risk have a hormonal basis? Cancer (Phila.), 75: 1778-1782, 1995.
29. Makridakis, N., Ross, R. K., Pike, M. C., Chang, L., Stanczyk, F. Z., Kolonel, L. N., Shi, C-Y., Yu, M. C., Henderson, B. E., and Reichardt, J. K. V. A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res., 57: 1020-1022, 1997.
30. Irvine, R. A., Yu, M. C., Ross, R. K., and Coetzee, G. A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937-1940, 1995.
31. La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E., and Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (Lond.), 352: 77-79, 1991.
32. Arbizu, T., Santamaria, J., Gomex, J. M., Quilez, A., and Serra, J. P. A family with adult spinal and bulbar muscular atrophy X-linked inheritance and associated with testicular failure. J. Neurol. Sci., 59: 371-382, 1983.
33. Nagashima, T., Seko, K., and Hirose, K. Familial bulbo-spinal muscular atrophy associated with testicular atrophy and sensory neuropathy: autopsy case report of two brothers. J. Neurol. Sci., 87: 141-152, 1988.
34. Tut, T. G., Ghadessey, F. J., Trifiro, M. A., Pinsky, L., and Yong, E. L. Long polyglutamine tracts in the androgen receptor are associated with reduced transactivation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab., 82: 3777-3782, 1997.
35. Coetzee, G. A., and Ross, R. K. Prostate cancer and the androgen receptor. J. Natl. Cancer Inst., 86: 872-873, 1994.
36. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 89: 166-170, 1997.
37. Stanford, J. L., Just, J. J., Gibbs, M., Wicklund, K. G., Neal, C. L., Blumenstein, B. A., and Ostrander, E. A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res., 57: 1194-1198, 1997.
38. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 3320-3323, 1997.
39. Hardy, D. O., Scher, H. I., Bogenreider, T., Sabbatini, P., Zhang, Z. F., Nanus, D. M., and Catterall, J. F. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab., 81: 4400-4405, 1996.
40. Hakimi, J. M., Schoenberg, M. P., Rondinelli, R. H., Piantadosi, S., and Barrack, E. R. Androgen receptor variants with short glutamine or glycine repeats identify unique subpopulations of men with prostate cancer. Clin. Cancer Res., 3: 1599-1608, 1997.
41. Mhatre, A. N., Trifiro, M. A., Kaufman, M., Kazemi-Esfarjani, P., Figlewicz, D., Rouleau, G., and Pinsky, L. Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat. Genet., 5: 184-188, 1993.
42. Chamberlain, N. C., Driver, E. D., and Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res., 22: 3181-3186, 1994.
43. Chamberlain, N. C., Whitacre, D. C., and Miesfeld, R. L. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain. J. Biol. Chem., 271: 26772-26778, 1996.
44. Monroe, K. R., Yu, M. C., Kolonel, L. N., Coetzee, G. A., Wilkens, L. R., Ross, R. K., and Henderson, B, E, Evidence of an X-linked genetic component to prostate cancer risk. Nat. Med., 1: 827-829, 1995.
45. Narod, S. A., Dupont, A., Cusan, L., Diamond, P., Gomez, J. L., Suburu, R., and Labrie, F. The impact of family history on early detection of prostate cancer. Nat. Med., 1: 99-101, 1995.
46. Sun, S., Narod, S. A., Aprikian, A., Ghadirian, P., and Labrie, F. Androgen receptor and familial prostate cancer. Nat. Med., 1: 848-849, 1995.
47. Smith, J. R., Freije, D., Carpten, J. D., Gronberg, H., Xu, J., Isaacs, S. D., Brownstein, M. J., Bova, G. S., Guo, H., Bujnovszky, P., Nusskern, D. R., Damber, J. E., Bergh, A., Emanuelsson, M., Kallioniemi, O. P., Walker-Daniels, J., Bailey-Wilson, J. E., Beaty, T. H., Meyers, D. A., Walsh, P. C., Collins, F. S., Trent, J. M., and Isaacs, W. B. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Washington DC), 274: 1371-1374, 1996.
48. Lu, J., and Danielsen, D. Short report on DNA marker at candidate locus: a Stu I polymorphism in the human androgen receptor gene (AR). Clin. Genet., 49: 323-324, 1996.
49. Carey, A. H., Waterworth, D., Patel, K., White, D., Little, J., Novelli, P., Franks, S., and Williamson, R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum. Mol. Genet., 3: 1873-1876, 1994.
50. Kadonaga, J. T., Jones, K. A., and Tjian, R. Promoter-specific activation of RNA polymerase II transcription by SpI. Trends Biochem. Sci., 11: 20-23, 1986.
51. Feigelson, H. S., Coetzee, G. A., Kolonel, L. N., Ross, R. K., and Henderson, B. E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res., 57: 1063-1065, 1997.
52. Geissler, W. M., Davis, D. L., Wu, L., Bradshaw, K. D., Patel, S., Mendonca, B. B., Elliston, K. O., Wilson, J. D., Russel, D. W., and Andersson, S. Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nat. Genet., 7: 34-39, 1994.
53. Labrie, F., Simard, J., Luu-The, V., Belanger, A., and Pelletier, G. Structure, function and tissue-specific expression of 3B-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine and steroidogenic tissue. J. Steroid Biochem. Mol. Biol., 43: 805-826, 1982.
54. Rheaume, E., Simard, J., Morel, Y., Mebarki, F., Zachmann, M., Forest, M. G., New, M. I., and Labrie, F. Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene. Nat. Genet., 1: 239-245, 1992.
55. Verreault, H., Dufort, I., Simard, J., Labrie, F., and Luu-The, V. Dinucleotide repeat polymorphisms in the HSD3B2 gene. Hum. Mol. Genet., 3: 384, 1994.
56. Devgan, S. A., Henderson, B. E., Yu, M. C., Shi, C-Y., Pike, M. C., Ross, R. K., and Reichardt, J. K. Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate, 33: 9-12, 1997.
57. Dai, W. S., Kuller, L. H., LaPorte, R. E., Gutai, J. P., Falvo-Gerard, L., and Caggiula, A. The epidemiology of plasma testosterone levels in middle-aged men. Am. J. Epidemiol., 114: 804-816, 1981.
58. Morley, J. E., Kaiser, F., Raum, W. J., Perry, H. M., III, Flood, J. F., Jensen, J., Silver, A. J., and Roberts, E. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc. Natl. Acad. Sci. USA, 94: 7537-7542, 1997.
59. vom Saal, F. S., Finch, C. E., and Nelson, J. F. Natural history and mechanisms of reproductive aging in humans, laboratory rodents and other selected vertebrates. In: E. Knobiland and J. D. Neil (eds.), The Physiology of Reproduction, pp. 1213-1314. New York: Raven Press, Ltd., 1994.
60. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollack, M. Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science (Washington DC), 279; 563-566, 1998.
61. Andersson, S., Geissler, W. M., Wu, L., Davis, D. L., Grumbach, M. M., New, M. I., Schwarz, H. P., Blethen, S. L., Mendonca, B. B., Bloise, W., Witchel, S. F., Cutler, G. B., Jr., Griffin, J. E., Wilson, J. D., and Russel, D. W. Molecular genetics and pathophysiology of 17β-hydroxysteroid dehydrogenase 3 deficiency. J. Clin. Endocrinol. Metab., 81: 130-136, 1996.
62. Cutler, S. J., and Young, J. L. Third National Cancer Survey: incidence data. NCI Monogr., 41: 106-111, 1975.